GlassScriptPhysician profile
Conor Joseph Mulcahy
NPI 1811168024
$6,749.09
in general payments reported to CMS, 2019-2025
44 companies · $21.27 in 2025
The $21.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $581 · 2021: $933 · 2022: $1,652 · 2023: $1,469 · 2024: $1,043 · 2025: $21.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.62 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,215.38 | 2019-2024 | |
| Novo Nordisk INC | $841.17 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $446.94 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $426.74 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $368.75 | 2019-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $309.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $275.66 | 2019-2021 | |
| Amgen INC. | $250.02 | 2020-2024 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $229.50 | 2019-2025 | Watchman Flx |
| Astellas Pharma US INC | $197.65 | 2020-2024 | Myrbetriq, Veozah |
| Lilly USA, LLC | $185.64 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $179.94 | 2019-2021 | |
| Eisai INC. | $150.33 | 2020-2024 | |
| Daiichi Sankyo INC. | $145.52 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $135.96 | 2019-2024 | Verquvo, Gardasil 9, Pneumovax 23 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conor Mulcahy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.